{{short description|British multinational consumer healthcare company}} {{Use dmy dates|date=July 2024}} {{Use British English|date=July 2024}} {{Infobox company | name = Haleon plc | logo = Haleon.svg | image = Brooklands office block, 22 July 2012 (2) (cropped).jpg | image_caption = Headquarters in Weybridge, UK | former_name = | type = Public limited company | traded_as = {{ubl|{{lse|HLN}}|{{nyse|HLN}}|FTSE 100 component}} | ISIN = GB00BMX86B70 | predecessors = {{ubl|GSK Consumer Healthcare (SmithKline Beecham Consumer Healthcare|Novartis Consumer Healthcare|Bristol-Myers Squibb Consumer Healthcare|Glaxo Wellcome Consumer Healthcare{{efn|In 1993, Warner Lambert and Wellcome created a joint venture with both companies merging their OTC products into a joint venture, the Wellcome OTC brands such as Calpol and Actifed; Glaxo also made a agreement with Warner Lambert in 1994 for the distribution of Zantac.<ref>{{cite news|url=https://www.nytimes.com/1993/12/21/business/company-news-warner-lambert-and-wellcome-sign-joint-venture-deal.html|title=Warner-Lambert and Wellcome sign joint venture deal|newspaper=New York Times|date=21 December 1993|access-date=29 May 2026}}</ref> In 1995, Glaxo and Wellcome merged to form Glaxo Wellcome which saw its OTC joint venture with Warner Lambert to now include Calpol, Actifed, and Zantac. In 1996, Warner Lambert bought out Glaxo Wellcome's stake in the joint venture, this caused Calpol, Actifed, and Zantac to be owned by Warner Lambert in most countries, however Glaxo Wellcome retained their OTC division in select countries such as the Philippines, Indonesia and South Africa.<ref>{{cite news|url=https://www.latimes.com/archives/la-xpm-1996-07-02-fi-20484-story.html|title=Warner-Lambert Buys Glaxo Drug Venture Stake in U.S., Europe|date=2 July 1996|newspaper=LA Times|access-date=29 May 2026}}</ref><ref>{{cite news|url=https://www.nytimes.com/1998/08/04/business/international-business-glaxo-and-warner-lambert-to-end-joint-venture.html|title=Glaxo and Warner-Lambert to End Joint Venture|newspaper=New York Times|date=4 August 1998|access-date=29 May 2026}}</ref> In 2000, Glaxo Wellcome and SmithKline Beecham merged to form GSK, in some countries where Glaxo Wellcome retained their OTC division, the remaining OTC division of Glaxo Wellcome also merged with SmithKline Beecham's OTC.<ref>{{cite news|url=http://news.bbc.co.uk/1/hi/business/607187.stm|title=The Glaxo SmithKline merger|newspaper=BBC News|date=17 January 2000|access-date=29 May 2026}}</ref>|group=note}}|Block Drug)|Pfizer Consumer Healthcare{{efn|Pfizer had previously sold its consumer health division (which had included in its portfolio such brands as Listerine, Benadryl, Visine, Combantrin, Mylanta, Nicorette, Sudafed,<ref name = "nyt 2009-01-23">{{cite news|last=Sorkin|first=Andrew Ross|date=January 23, 2009|title=Pfizer said to be closing in on deal for Wyeth|work=The New York Times|url=https://www.nytimes.com/2009/01/24/business/24drug.html|access-date=May 8, 2023}}</ref> Rogaine, Rolaids, and Zantac)<ref name = "nyt 2006-06-27">{{cite news|last=Saul|first=Stephanie|date=June 27, 2006|title=Johnson & Johnson buys Pfizer unit for $16.6 billion|work=The New York Times|url=https://www.nytimes.com/2006/06/27/business/27johnson.html|access-date=May 8, 2023}}</ref> to Johnson & Johnson in 2006,<ref name = "nyt 2006-06-27"/> but re-entered the consumer health industry when it acquired Wyeth (whose consumer health division had included in its portfolio such brands as Advil, Centrum, ChapStick, Dimetapp, and Robitussin)<ref name = "nyt 2009-01-23"/> in 2009.<ref name = "reuters 2009-01-25">{{cite news|last1=Hall|first1=Jessica|last2=Krauskopf|first2=Lewis|date=January 25, 2009|title=Pfizer to buy Wyeth for $68 billion|work=Reuters|url=https://www.reuters.com/article/us-wyeth-pfizer/pfizer-to-buy-wyeth-for-68-billion-idUSTRE50M1AQ20090126|access-date=May 8, 2023}}</ref><ref name = "nyt 2009-01-26">{{cite news|last1=Sorkin|first1=Andrew Ross|last2=Wilson|first2=Duff|date=January 26, 2009|title=Pfizer to acquire Wyeth for $68 billion|work=The New York Times|url=https://www.nytimes.com/2009/01/26/business/worldbusiness/26iht-drug.4.19689943.html|access-date=May 8, 2023}}</ref> It later sold its consumer health division again to GSK plc.<ref>{{cite web|url=https://ec.europa.eu/commission/presscorner/detail/sv/ip_19_4030|title=Mergers: Commission approves GlaxoSmithKline's acquisition of Pfizer's Consumer Health Business, subject to conditions|publisher=European Commission|access-date=29 May 2026}}</ref>|group=note}} (Wyeth Consumer Healthcare)}} | area_served = Worldwide | key_people = {{plainlist| * Sir Dave Lewis (chairman) * Brian McNamara (CEO) }} | industry = {{ubl|Healthcare|Consumer goods}} | products = {{hlist|Oral hygiene and medicines|nutritional products|over-the-counter medicines}} | brands = {{flatlist| * Actifed * Advil * Aquafresh * Beechams * Biotene * Caltrate * Centrum * Contac * Emergen-C * Eno * Excedrin * Fenbid * Fenistil * Flonase * Foodles * Loviscol * Maclean * Nexium * Nicorette * Nicotinell * Odol * Otrivin * Panadol * Parodontax * Polident * Sensodyne * Theraflu * Tums * Voltaren }} | revenue = {{decrease}} £11,030 million (2025)<ref name="results">{{cite web|title=Annual results 2025|url=https://www.haleon.com/content/dam/haleon/corporate/documents/investors/results/full-year-results-2025/fy25-statement.pdf.downloadasset.pdf|publisher=Haleon|access-date=25 February 2026}}</ref> | operating_income = {{increase}} £2,412 million (2025)<ref name="results"/> | net_income = {{increase}} £1,680 million (2025)<ref name="results"/> | assets = {{decrease}} £32,630 million (2025)<ref name="results"/> | equity = {{increase}} £16,484 million (2025)<ref name="results"/> | num_employees = 24,000 (2024)<ref>{{cite news |url=https://www.reuters.com/business/healthcare-pharmaceuticals/sensodyne-maker-haleon-shut-uk-manufacturing-site-with-more-than-400-jobs-hit-2024-04-30/ |title=Sensodyne-maker Haleon to shut UK plant, 435 jobs to go |date=30 April 2024 |newspaper=Reuters|access-date=9 February 2025}}</ref> | owners = | divisions = | subsid = Haleon Pakistan | foundation = {{start date and age|2022|07|18|df=yes}} | location = Weybridge, England, United Kingdom | website = {{URL|https://www.haleon.com}} }}
'''Haleon plc''' is a British multinational consumer healthcare company with headquarters in Weybridge, England.<ref>{{Cite web |title=GSK announces independent Consumer Healthcare company is to be called Haleon |url=https://www.gsk.com/en-gb/media/press-releases/gsk-announces-independent-consumer-healthcare-company-is-to-be-called-haleon/ |access-date=2023-02-21 |website=www.gsk.com |date=22 February 2022 |language=en-GB |archive-date=21 February 2023 |archive-url=https://web.archive.org/web/20230221203149/https://www.gsk.com/en-gb/media/press-releases/gsk-announces-independent-consumer-healthcare-company-is-to-be-called-haleon/ |url-status=live }}</ref> It is one of the largest consumer healthcare businesses in the world, with brands including Sensodyne toothpaste, Panadol and Advil painkillers, and Centrum vitamins.<ref>{{cite news |last1=Ralph |first1=Alex |title=GlaxoSmithKline prepares to get back to basics with historic break-up |url=https://www.thetimes.com/uk/healthcare/article/three-centuries-of-gsk-story-about-to-add-a-new-chapter-3jrbn8kkq |access-date=4 July 2022 |work=The Times |date=2 July 2022 |archive-date=5 August 2023 |archive-url=https://web.archive.org/web/20230805105647/https://www.thetimes.co.uk/article/three-centuries-of-gsk-story-about-to-add-a-new-chapter-3jrbn8kkq |url-status=live }}</ref> The company was projected to be a global leader in over the counter medicines with a 7.3 per cent market share in 2022.<ref name="forbes1">{{cite news |last1=Cornell |first1=Joe |title=GlaxoSmithKline To Spin-Off Consumer Healthcare Business By Mid-2022 |url=https://www.forbes.com/sites/joecornell/2021/07/15/glaxosmithkline-to-spin-off-consumer-healthcare-business-by-mid-2022/?sh=723ac83372d0 |access-date=10 June 2022 |work=Forbes |date=15 July 2021 |archive-date=11 February 2023 |archive-url=https://web.archive.org/web/20230211180517/https://www.forbes.com/sites/joecornell/2021/07/15/glaxosmithkline-to-spin-off-consumer-healthcare-business-by-mid-2022/?sh=723ac83372d0 |url-status=live }}</ref>
Haleon was established on 18 July 2022 as a corporate spin-off from GSK.<ref>{{cite web|title=Prospectus|url=https://www.gsk.com/media/7702/haleon-plc-prospectus.pdf|publisher=GSK plc|page=15|access-date=10 June 2022|archive-date=1 June 2022|archive-url=https://web.archive.org/web/20220601125715/https://www.gsk.com/media/7702/haleon-plc-prospectus.pdf|url-status=dead}}</ref> Haleon is listed on the London Stock Exchange and is a component of the FTSE 100, with a secondary listing on the New York Stock Exchange.
==History== GSK and Pfizer merged their consumer healthcare businesses in 2019.<ref name="cnn1">{{cite news |last1=Shane |first1=Daniel |title=Advil meet Excedrin: Pfizer and GSK are merging their consumer healthcare businesses |url=https://edition.cnn.com/2018/12/19/business/pfizer-gsk-healthcare/index.html |access-date=10 June 2022 |work=CNN |date=19 December 2018 |archive-date=6 June 2023 |archive-url=https://web.archive.org/web/20230606095307/https://edition.cnn.com/2018/12/19/business/pfizer-gsk-healthcare/index.html |url-status=live }}</ref><ref>{{cite news|url=https://www.barrons.com/articles/haleon-wont-indemnify-pfizer-gsk-zantac-51663686390|title=Haleon Won't Indemnify Pfizer, GSK Over Zantac. Shares Are Up.|newspaper=Barron's|date=20 September 2022|access-date=17 December 2022|archive-date=10 November 2022|archive-url=https://web.archive.org/web/20221110142351/https://www.barrons.com/articles/haleon-wont-indemnify-pfizer-gsk-zantac-51663686390|url-status=live}}</ref> GSK owned just over two thirds of the joint venture, and Pfizer owned the remainder.<ref name="cnn1"/> Annual sales were around £10 billion across 120 markets in 2020.<ref name="forbes1" /> GSK then announced plans to spin off Haleon in 2022 to give the "tired drugmaker extra focus and firepower by gearing up and hiving off the consumer division," according to Reuters.<ref name="reuters1">{{cite news |last1=Donnellan |first1=Aimee |title=GSK castoff starts life with target on its back |url=https://www.reuters.com/breakingviews/gsk-castoff-starts-life-with-target-its-back-2022-06-09/ |access-date=10 June 2022 |work=Reuters |date=9 June 2022 |archive-date=22 September 2022 |archive-url=https://web.archive.org/web/20220922114359/https://www.reuters.com/breakingviews/gsk-castoff-starts-life-with-target-its-back-2022-06-09/ |url-status=live }}</ref> Unilever offered £50 billion for the business in 2022, which GSK rejected.<ref name="guardian1">{{cite news |last1=Jolly |first1=Jasper |title=Unilever will not increase £50bn offer for GSK consumer arm |url=https://www.theguardian.com/business/2022/jan/19/unilever-will-not-increase-50bn-offer-for-gsk-consumer-arm |access-date=10 June 2022 |work=The Guardian |date=19 January 2022 |archive-date=18 October 2022 |archive-url=https://web.archive.org/web/20221018002210/https://www.theguardian.com/business/2022/jan/19/unilever-will-not-increase-50bn-offer-for-gsk-consumer-arm |url-status=live }}</ref> Nestlé examined the possibility of a bid in conjunction with Reckitt.<ref name="bloomberg1">{{cite news |title=Nestle Eyed Biggest-Ever Deal in Aborted Move for GSK Unit |url=https://www.bloomberg.com/news/articles/2022-05-25/nestle-eyed-biggest-ever-deal-in-aborted-move-for-gsk-consumer#xj4y7vzkg |access-date=10 June 2022 |work=Bloomberg News |date=25 May 2022 |archive-date=30 April 2023 |archive-url=https://web.archive.org/web/20230430142405/https://www.bloomberg.com/news/articles/2022-05-25/nestle-eyed-biggest-ever-deal-in-aborted-move-for-gsk-consumer#xj4y7vzkg |url-status=live }}</ref> In October 2023, GSK reduced its ownership in Haleon to 7.4%,<ref>{{Cite news |date=2023-10-06 |title=GSK raises $1.1 billion from Haleon stake sale |language=en |work=Reuters |url=https://www.reuters.com/markets/deals/gsk-raises-886-mln-pounds-haleon-stake-sale-2023-10-06/ |access-date=2023-10-09 |archive-date=7 October 2023 |archive-url=https://web.archive.org/web/20231007060118/https://www.reuters.com/markets/deals/gsk-raises-886-mln-pounds-haleon-stake-sale-2023-10-06/ |url-status=live }}</ref> and in January 2024 it further reduced its ownership to 4.2%.<ref>{{Cite news |date=2024-01-17 |title=GSK raises $1.24 bln from latest Haleon stake sale |language=en |work=Reuters |url=https://www.reuters.com/markets/deals/gsk-sell-32-stake-spin-off-haleon-2024-01-16/ |access-date=2024-01-18}}</ref>
In August 2023, Haleon sold its Lamisil antifungal brand to Karo Healthcare AB for £235 million,<ref>{{cite web |author=<!--staff writer--> |title=Karo Healthcare acquires the Global OTC brand Lamisil® from Haleon |url=https://www.karohealthcare.com/karo-healthcare-acquires-the-global-otc-brand-lamisil-from-haleon/ |website=Karo Healthcare |access-date=5 June 2024 |date=2 August 2023 |archive-date=5 June 2024 |archive-url=https://web.archive.org/web/20240605172814/https://www.karohealthcare.com/karo-healthcare-acquires-the-global-otc-brand-lamisil-from-haleon/ |url-status=live }}</ref><ref>{{cite web |author=<!--staff writer-->|title=Karo Healthcare completes the acquisition of the rights to the Global OTC brand Lamisil® from Haleon |url=https://www.karohealthcare.com/karo-healthcare-completes-the-acquisition-of-the-rights-to-the-global-otc-brand-lamisil-from-haleon/ |website=Karo Healthcare |access-date=5 June 2024 |date=1 November 2023 |archive-date=5 June 2024 |archive-url=https://web.archive.org/web/20240605120724/https://www.karohealthcare.com/karo-healthcare-completes-the-acquisition-of-the-rights-to-the-global-otc-brand-lamisil-from-haleon/ |url-status=live }}</ref> and in February 2024, Haleon sold its ChapStick lip care brand to Yellow Wood Partners for £401 million.<ref name="chapsticksale">{{cite news |last1=Williams |first1=Holly |title=Haleon offloads ChapStick lip balm brand in £401m deal |url=https://www.standard.co.uk/business/business-news/haleon-offloads-chapstick-lip-balm-brand-in-ps401m-deal-b1134719.html |access-date=20 February 2024 |work=The Standard |date=25 January 2024 |archive-date=20 February 2024 |archive-url=https://web.archive.org/web/20240220110819/https://www.standard.co.uk/business/business-news/haleon-offloads-chapstick-lip-balm-brand-in-ps401m-deal-b1134719.html |url-status=live }}</ref>
In March 2024, Pfizer reduced its share in Haleon from 32% to 24% per cent by selling 630 million shares in a public offering.<ref>{{Cite web |date=2024-03-18 |title=Pfizer to cut stake in Sensodyne toothpaste-maker Haleon to 24% |url=https://finance.yahoo.com/news/consumer-healthcare-giant-haleon-says-070910309.html |access-date=2024-03-19 |website=Yahoo Finance |language=en-US |archive-date=19 March 2024 |archive-url=https://web.archive.org/web/20240319082431/https://finance.yahoo.com/news/consumer-healthcare-giant-haleon-says-070910309.html |url-status=live }}</ref>
Further sales followed: in April 2024, Haleon announced that it would close its Sensodyne toothpaste factory in Maidenhead,<ref name="bbc1">{{cite news |last1=Briant |first1=Nathan |title=Sensodyne maker set to cut 435 jobs |url=https://www.bbc.co.uk/news/articles/cd186rrgjxko |access-date=8 May 2024 |work=BBC News |date=30 April 2024 |archive-date=8 May 2024 |archive-url=https://web.archive.org/web/20240508105942/https://www.bbc.co.uk/news/articles/cd186rrgjxko |url-status=live }}</ref> moving that manufacturing to Slovakia, and it outsourced mouthwash manufacturing to an unrelated company<ref name="reuters2">{{cite news |last1=Mathews |first1=Eva |title=Sensodyne-maker Haleon to shut UK plant, 435 jobs to go |url=https://www.reuters.com/business/healthcare-pharmaceuticals/sensodyne-maker-haleon-shut-uk-manufacturing-site-with-more-than-400-jobs-hit-2024-04-30/ |access-date=8 May 2024 |work=Reuters |date=30 April 2024}}</ref> and, in September 2024, the company completed the sale of its non-US nicotine replacement therapy business to Dr. Reddy's Laboratories in a deal worth £458 million.<ref>{{Cite web |title=Dr Reddy's Laboratories completes acquisition of Haleon's NRT portfolio |url=https://www.business-standard.com/companies/news/dr-reddy-s-laboratories-completes-acquisition-of-haleon-s-nrt-portfolio-124093000809_1.html |date=30 September 2024 |access-date=25 November 2024 |publisher=Business Standard |work=Press Trust of India |language=en |archive-date=29 October 2024 |archive-url=https://web.archive.org/web/20241029035249/https://www.business-standard.com/companies/news/dr-reddy-s-laboratories-completes-acquisition-of-haleon-s-nrt-portfolio-124093000809_1.html |url-status=live }}</ref>
In March 2025, Pfizer sold its entire stake in Haleon for £2.5 billion ($3.24 billion), exiting the consumer healthcare business it helped create by its 2019 joint venture with GSK.<ref>{{Cite web |title=Pfizer sells entire Haleon stake for $3.24 billion |website=Reuters |url=https://www.reuters.com/business/healthcare-pharmaceuticals/pfizer-sells-entire-haleon-stake-324-billion-2025-03-19/}}</ref><ref>{{Cite web |date=2025-03-19 |title=Pfizer sells entire Haleon stake for £2.5 billion |url=https://www.rte.ie/news/business/2025/0319/1502825-pfizer-sells-entire-haleon-stake-for-l2-5-billion/ |language=en}}</ref><ref>{{Cite web |author=<!--staff writer--> |date=2025-03-19 |title=Pfizer offloads Haleon shares in $3.24 billion deal |url=https://profit.pakistantoday.com.pk/2025/03/19/pfizer-offloads-haleon-shares-in-3-24-billion-deal/ |access-date=2025-03-20 |website=Profit by Pakistan Today |language=en-US}}</ref>
==Operations== Oral health accounted for 28.5 percent of revenue in 2021.<ref name="gsk1">{{cite web |title=Update: Proposed demerger of the Consumer Healthcare business from GSK to form Haleon |url=https://www.gsk.com/en-gb/media/press-releases/update-proposed-demerger-of-the-consumer-healthcare-business-from-gsk-to-form-haleon/ |website=GSK |date=6 January 2022 |access-date=10 June 2022 |archive-date=29 March 2023 |archive-url=https://web.archive.org/web/20230329162356/https://www.gsk.com/en-gb/media/press-releases/update-proposed-demerger-of-the-consumer-healthcare-business-from-gsk-to-form-haleon/ |url-status=live }}</ref>
Sir Dave Lewis is chairman, with Brian McNamara as chief executive.<ref name="haleonsky">{{cite news |last1=Kleinman |first1=Mark |date=3 May 2022 |title=GSK's £45bn Panadol and Sensodyne-maker Haleon in talks to hire banks |url=https://news.sky.com/story/gsks-45bn-panadol-and-sensodyne-maker-haleon-in-talks-to-hire-banks-12604875 |url-status=live |archive-url=https://web.archive.org/web/20230211180519/https://news.sky.com/story/gsks-45bn-panadol-and-sensodyne-maker-haleon-in-talks-to-hire-banks-12604875 |archive-date=11 February 2023 |access-date=10 June 2022 |work=Sky News}}</ref>
==Brands== [[File:Aquafresh - GSK.jpg|250px|thumb|A selection of Aquafresh toothpaste and toothbrushes produced by Haleon]]
===Current=== Brands include:<ref>{{cite web |url=https://www.haleon.com/our-brands/ |title=Our Consumer Healthcare Brands |accessdate=19 July 2022 |publisher=Haleon |archive-date=2 August 2023 |archive-url=https://web.archive.org/web/20230802200854/https://www.haleon.com/our-brands |url-status=live }}</ref> {{Columns-list|colwidth=25em| * Abreva (Docosanol) * Advil (Ibuprofen) * alli (Orlistat) * Anadin (pain relief) * Aquafresh (oral healthcare) * Astring-o-Sol (oral healthcare) * Be-Total (leader in vitamins market in Italy) * Beechams Cold & Flu and Night/Day Nurse (cold and flu treatments) * Biotene (oral healthcare) * Boost (nutritional) * Breathe Right (respiratory) * Calpol (fever medicine) * Caltrate (bone and joint supplement) * Centrum (vitamins and naturals) * Cetebe (vitamins and naturals) * Chlorhexamed (oral healthcare) * Cholinex (analgesics and respiratory tract) * Citrucel (gastrointestinal) * Clusivol (multivitamins) ** Clusivol Plus (mutivitamins) ** Clusivol OB (multivitamins for pregnant and lactating women) ** Children's Clusivol (multivitamins for children) * Coldrex (cold and flu treatment) * Commit Lozenge (smoking cessation) * Committed Quitters (nicotine replacement) * Corega (oral healthcare) * Corsodyl (oral healthcare) * Crocin (analgesics and respiratory tract) * Dr. Best (oral healthcare) * Emergen-C * ENO (gastrointestinal) * Eroxon * Eumovate (dermatological) * Excedrin * Fenistil * Fenbid (analgesics and respiratory tract) * Fibrosine (constipation relief) * Flonase (fluticasone propionate) * Foodles (noodles), origin: India * Formigran (analgesic/triptan) * Grand-PA (headache/toothache/pain and fever) * Hinds (dermatological) * Imedeen * Iodex (pain relief) * Iodosan (cold and flu treatment) * Junior Horlicks (nutritional) * Loviscol (cough suppressant) * Macleans (oral healthcare) * Maltova (nutritional) * Maxinutrition (nutritional) * Med-Lemon (hot, cold and flu medication) * Medacalm (vitamins and naturals) * Nexium Control (esomeprazole) * Nicorette (nicotine replacement) * Night Nurse (cold and flu remedy) * NiQuitin CQ/ Nicoderm CQ/ Nicabate (nicotine replacement) * Odol (oral healthcare) * Odol-med3 (oral healthcare) * Os-cal (vitamins and minerals) * Otrivin/Otrivine (xylometazoline) * Panadeine (analgesics and respiratory tract) * Panadol/Panodil (analgesics and respiratory tract) * Parodontax (oral healthcare) * Piriton/Piriteze/Pirinase (anti-allergy) * Polident (oral healthcare) * Poligrip Ultra (oral healthcare) * Robikids (kids’ cough medicine) * Robitussin (respiratory medicine) * Rutinoscorbin (vitamins and naturals) * Scott's (vitamins and naturals) * Sensodyne (oral healthcare) * Shumitect (oral healthcare) * Simeco (gastrointestinal) * Sinecod (cough medicine) * Solpadeine (analgesics and respiratory tract) * Stresstabs (stress reliever) * Super Poligrip (oral healthcare) * Super Wernet's (oral healthcare) * Synthol (oral healthcare) * Theraflu (Respiratory) * TriHEMIC (anemia medicine) * Tums (gastrointestinal) * Viva (vitamins and naturals), origin: Nepal * Voltaren/Voltarol (anti inflammatory) * Zovirax (dermatological) }}
===Divested=== {{Columns-list| * ChapStick (sold to Suave Brands Company in 2024)<ref>{{Cite web|url=https://www.cosmeticsdesign.com/Article/2024/06/05/suave-brands-company-successfully-completes-acquisition-of-1-lip-care-brand-chapstick|title=Suave Brands Company successfully completes acquisition of #1 lip care brand ChapStick|work=Cosmetics Design USA|date=5 June 2024 |access-date=2024-10-21|language=en}}</ref> * Lamisil (terbinafine) (sold to Karo Healthcare in 2023) * Nicotinell (sold to Dr Reddy's Laboratories in 2024) }}
==Notes== {{Notelist|group=note}}
==References== {{reflist|2}}
==External links== * {{Official website|https://www.haleon.com}} {{Finance links | symbol = HLN | sec_cik = 1900304 | yahoo = HLN.L | bloomberg = HLN:LN | reuters = HLN.L }}
{{Haleon}} {{GlaxoSmithKline}} {{FTSE 100 Index constituents}} {{authority control|state=expanded}}
Category:Haleon Category:2022 establishments in England Category:Companies based in Surrey Category:Companies listed on the London Stock Exchange Category:Corporate spin-offs Category:Dental companies of the United Kingdom Category:Health care companies of England Category:Manufacturing companies of England Category:Manufacturing companies established in 2022 Category:Multinational companies headquartered in England Category:Personal care companies of the United Kingdom Category:Weybridge Category:Companies in the FTSE 100 Index Category:British companies established in 2022